Exploratory Tau Biomarker Results From a Study of BIIB080 in Alzheimer Disease

Дата публикации: 01-12-2023 00:00:00

This randomized clinical trial examines data from patients with mild Alzheimer disease receiving BIIB080 to assess changes in tau biomarkers associated with cognitive decline, including cerebrospinal fluid total tau and phosphorylated tau 181 and tau positron emission tomography.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Deferiprone in Alzheimer Disease	0	10.42	01-01-2025
2	p-Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation	0	15.37	01-09-2024
3	Tau levels fall, cognitive decline slows with diranersen	0	9.46	04-08-2026
4	Tau Oligomer–Containing Synapses Engulfed by Microglia and Astrocytes in Alzheimer Disease	0	7.6	01-11-2023
5	Teriflunomide and Time to Clinical Multiple Sclerosis in Radiologically Isolated Syndrome	0	6.92	01-10-2023
6	Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment	0	14.88	14-07-2026
7	Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease	0	13.04	14-07-2026
8	New experimental Alzheimer’s drug shows potential after study shows slower cognitive decline	2	6	14-07-2026
9	An experimental Alzheimer's drug shows promise targeting a different brain protein, new study shows	0	6.02	14-07-2026
10	An experimental Alzheimer's drug shows promise targeting a different brain protein, new study shows	2	7	14-07-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10.76. Источник: archderm.jamanetwork.com.